CME/MOC/CC/AAPA Credit: A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC

Sunday, January 28, 2024

5:55 AM – 6:55 AM CT

Location: Grand Hyatt San Antonio, Lone Star Ballroom EF

Supporter Statement:
This CME/MOC/CC/AAPA activity is provided by PVI, PeerView Institute for Medical Education. This activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.

Activity Description:
The expanding evidence base supporting the use of neoadjuvant, adjuvant, and combined perioperative immunotherapy has reshaped the standards of care in surgically resectable NSCLC and led to several regulatory approvals. The potential of immune checkpoint inhibitors to reduce the risk of recurrence and improve other outcomes in the curative intent settings represents a notable advance, but these new options have also contributed to increasing complexity in therapeutic decision-making in practice.

This PeerView Live Modern Practice Principles educational symposium will bring together a panel of multidisciplinary experts to analyze and interpret the latest practice-changing evidence on neoadjuvant, adjuvant, and combined perioperative immunotherapy in resectable NSCLC from different perspectives. Real-world cases will be used to demonstrate how to apply the data to practice and work with the other members of the lung cancer care team to make the best treatment decisions for each patient at the right time.

To learn more and to register, visit PeerView.com/2024ImmunoOnc-Live.

Co-Chair(s)

Jessica S. Donington, MD (she/her/hers)

Chief Thoracic Surgery
University of Chicago
Chicago, Illinois, United States

Disclosure(s): Amgen Inc.: Advisory Board (Terminated, October 20, 2023)
Jonathan David Spicer, MD, PhD, FRCSC

Associate Professor of Surgery
Division of Thoracic Surgery, McGill University
Montreal, Quebec, Canada

Disclosure(s): Amgen: Advisory Board (Ongoing), Speaker (Ongoing); Astrazeneca: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); CLS Therapeutics: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Eisai: Advisory Board (Terminated); MSD: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Protalix Biotherapeutics: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Regeneron: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Roche: Advisory Board (Terminated), Consultant (Terminated), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); xenetic biosciences: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)

Presenter(s)

Patrick M. Forde, MD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Disclosure information not submitted.